• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Modification of Multidrug Resistance by Magnetic Exposure Indicated from the Point of View of Nuclear Medicine

Research Project

Project/Area Number 09670954
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Radiation science
Research InstitutionKeio University

Principal Investigator

NAKAMURA Kayoko  Keio University School of Medicine; Radiology; Assistant Professor, 医学部, 専任講師 (20124480)

Project Period (FY) 1997 – 1998
Project Status Completed (Fiscal Year 1998)
Budget Amount *help
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 1998: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1997: ¥2,000,000 (Direct Cost: ¥2,000,000)
KeywordsMagnetic Exposure / Tumor / Chemosensitivity / Multidrug Resistance / Tc-99m-MIBI / P-glycoprotein / 抗がん剤 / P-糖たん白質 / P糖蛋白質
Research Abstract

The effects of magnetic field on the chemosensitivity of tumor cells were investigated by using Tc-99m-MIBI uptake; which indicates the function of P-glycoprotein. The cells lines studies were anaplastic thyroid cancer cell lines established from patients; human epidermoid cell KB-31; KB-31 transfected with mdr gene KB-G2; and MRP-cell line CA-500. By the strong magnetic exposure for a short period (one hour) the Tc-99m-MIBI uptake in some tumor cells (not all cells) was reduced. Under weak magnetic field the Tc-99m-MIBI uptake was increased in all tumor cells studied. These effects were not altered in the presence of anti-P-glycoprotein antibody or verapamil that inhibits the function of P-glycoprotein. It can be, therefore, concluded that the magnetic effects were different from cell to cell, and that these effects were not specific for P-glycoprotein. Magnetic exposure may be one of modifications that reverse multidrug resistance of tumor cells. Tc-99m-MIBI uptake in cells is a good indicator to assess the multidrug resistance modification.

Report

(3 results)
  • 1998 Annual Research Report   Final Research Report Summary
  • 1997 Annual Research Report
  • Research Products

    (30 results)

All Other

All Publications (30 results)

  • [Publications] 中村佳代子: "核医学/最近の進歩:放射性医薬品"日本医学放射線学会雑誌. 57(5). 13-16 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 中村佳代子: "放射性医薬品の集積機序"核医学・技術. 17(4). 265-267 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 藤井博史、他: "Tc-99m-MIBIシンチグラフィによる乳癌多剤耐性の検討"免疫・腫瘍核医学. 12(1). 20-22 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 中村佳代子: "アメリカでの腫瘍・免疫核医学の最新トレンド"新医療. 26(3). 54-57 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] K.Nakamura et al.: "In vitro assessment of MDR-reversing agents by Tc-99m-MIBI or Tc-99m-Tetrofosmin"Journal of Nuclear Medicine. 38(5). 180P-181 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] H.Fujii et al.: "The preoperative prediction of the response to doxorubicin breast cancer using Tc-99m-MIBI"Journal of Nuclear Medicine. 38(5). 234P-235P (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] K.Nakamura et al.: "In vivo evaluation of P-glycoprotein by T-125-labelled MRK-16 monoclonal antibody or Tc-99m-MIBI"European Journal of Nuclear Medicine. 24(8). 869 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] H.Fujii et al.: "Preoperative evaluation of the chemosensitivity of breast cancer by means of double phase Tc-99m-MIBI scintimammography"Annals of Nuclear Medicine. 12(6). 307-312 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] K.Nakamura et al.: "Tc-99m-MIBI scintigraphy as an Indicator of the chemosensitivity of anthracyclines in patients with breast cancer"Anticancer Research. 18(6B). 4601-4605 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] K.Nakamura et al.: "Assessment of MDR-reversing agents by Tc-99m-MIBI"Anticancer Research. 18(6C). 4921 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] K. Nakamura: "Nuclear Medicine/Recent Progress : Radiopharmaceuticals"Journal of Japan Radiological Society. 57-5. 13-16 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] H. Fujii et al.: "Study of multidrug resistance of breast cancer by Tc-99m-MIBI scintimammography"Immuno/Nuclear Oncology. 12-1. 20-22 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] K. Nakamura: "Accumulation Mechanism of Radiopharmaceuticals"Nuclear Medicine and Technology. 17-4. 265-267 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] K. Nakamura et al.: "In vitro assessment of MDR-reversing agents by Tc-99m-MIBI or Tc-99m-Tetrofosmin"Journal of Nuclear Medicine. 38-5. 180-181 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] H. Fujii et al.: "The preoperative prediction of the response to doxorubicin for breast cancer using Tc-99m-MIBI"Journal of Nuclear Medicine. 38-5. 234-235 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] K. Nakamura et al.: "In vivo evaluation of P-glycoprotein by I-125-labelled MRK-16 monoclonal antibody or Tc-99m-MIBI"European Journal of Nuclear Medicine. 24-8. 869 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] H. Fujii et al.: "Preoperative evaluation of the chemosensitivity of breast cancer by means of double phase Tc-99m-MIBI scintimammography"Annals of Nuclear Mediceine. 12-6. 307-312 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] K. Nakamura et al.: "Tc-99m-MIBI scintigraphy as an indicator of the chemosensitivity of anthracyclines in patients with breast cancer"Anticancer Research. 18-6B. 4601-4605 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] K. Nakamura et al.: "Assessment of MDR-reversing agents by Tc-99m-MIBI"Anticancer Research. 18-6C. 4921 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] K. Nakamura: "Topics of Nuclear Oncology in USA"Shin-iryo. 26-3. 54-57 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Fuii H.,et al: "Preoperative evaluation of the chemosensitivity of breast cancer by means of double phase Tc-99m-MIBI scintimammography" Annals of Nuclear Medicine. 12(6). 307-312 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Nakamura K.et al,: "Tc-99m-MIBI Scintigraphy as An Indicator of The Chemosensitivity of Anthracyclines in Patients with Breast Cancer" Anticancer Research. 18(6B). 4601-4605 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Nakamura K.et al,: "Assessment of MDR-reversing Agents by Tc-99m-MIBI" Anticancer Researcg. 18(6C). 4921 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] 中村佳代子: "アメリカでの腫瘍・免疫核医学の最新トレンド" 新医療. 26(3). 54-57 (1999)

    • Related Report
      1998 Annual Research Report
  • [Publications] 中村佳代子: "核医学/最近の進歩:放射性医薬品" 日本医学放射線学会雑誌. 57(5). 13-16 (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] 藤井博史、他: "Tc-99m-MIBIシンチグラフィによる乳癌多剤耐性の検討" 免疫・腫瘍核医学. 12(1). 20-22 (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] 中村佳代子: "放射性医薬品の集積機序" 核医学・技術. 17(4). 265-267 (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] K.Nakamura,et al: "In vitro assessment of MDR-reversing agents by Tc-99m-MIBI or Tc-99m-Tetrofosmin" Journal of Nuclear Medicine. 38(5). 180P-181P (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] H.Fujii,et al: "The preoperative prediction of the response to doxorubicin for breast cancer using Tc-99m MIBI" Journal of Nuclear Medicine. 38(5). 234P-235P (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] K.Nakamura,et al: "In vivo evaluation of P-glycoprotein by I-125-labelled MRK-16 monoclonal antibody or Tc-99m-MIBI" European Journal of Nuclear Medicine. 24(8). 869- (1997)

    • Related Report
      1997 Annual Research Report

URL: 

Published: 1997-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi